Why the study?
Does candesartan reduce mortality and morbidity in patients with clinical heart failure?
Does candesartan reduce mortality and morbidity in patients with clinical heart failure?
This review summarizes evidence that candesartan is an effective treatment for reducing mortality and morbidity in heart failure, both as an alternative for ACE inhibitor-intolerant patients and as an add-on therapy.
May support ARB choice in ACE inhibitor-intolerant HF; leaves open head-to-head data versus newer agents.
Candesartan is an angiotensin receptor antagonist that is long acting, well absorbed from the gastrointestinal tract and demonstrates an insurmountable receptor antagonism. It is an effective once-daily antihypertensive therapy that maintains good control of blood pressure for over 24 h. More recently, candesartan was shown to be an effective therapy for heart failure patients, producing a significant reduction in mortality and morbidity. Importantly, the studies have demonstrated that candesartan is effective in heart failure patients intolerant to angiotensin-converting enzyme inhibitors (ACE-I), as well as in addition to ACE-I. This paper reviews the data supporting the use of candesartan to treat patients with clinical heart failure.
No takes yet. Share an insight, caveat, or question.
Robert S. McKelvie (2006) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: